[en] Second-generation (atypical) antipsychotic medications are of great benefit to a wide variety of people with psychiatric disorders, especially patients with schizophrenia. However, one constellation of adverse effects is an increased risk of obesity, diabetes, and metabolic syndrome. Increasing numbers of reports concerning impaired glucose tolerance, diabetes, and ketoacidosis have raised concerns about a possible association between abnormal glucose metabolism and treatment with atypical antipsychotics, although the question is still debated because of the presence of many confounding factors. A close relationship between drug-induced weight gain and risk of diabetes has been reported, emphasizing the role of insulin resistance. However, some cases of diabetes developed independently of weight gain, rather rapidly and possibly progressing to ketoacidosis, thus arguing for a severe impairment of insulin secretion. Another debated question is whether diabetes risk is a class action or a differential action. Although not fully scientifically proven yet, available evidence suggests that clozapine and olanzapine have a higher propensity to induce diabetes and metabolic syndrome compared with other atypical antipsychotic drugs, risperidone and quetiapine. Despite more limited available data, amisulpride, aripiprazole and ziprazidone showed less likelihood of precipitating diabetes. Interestingly, reversibility of drug-related diabetes has been reported with aripiprazole. The choice of atypical antipsychotic medication for a specific patient depends on many factors, but the likelihood of developing diabetes should become an important consideration. When prescribing an atypical antipsychotic, a commitment to careful baseline screening and follow-up monitoring is essential in order to mitigate the risk of developing diabetes and associated complications.
Disciplines :
Endocrinology, metabolism & nutrition Psychiatry
Author, co-author :
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
De Hert, M. A.
Language :
English
Title :
Abnormal glucose metabolism in patients treated with antipsychotics.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, and North American Association for the Study of Obesity. Consensus Development Conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27 (2004) 596-601
Scheen A.J., and De Hert M. Risque de diabète sucré sous antipsychotiques atypiques. Med. Hyg. (Geneve) 62 (2004) 1591-1596
Citrome L.L., and Jaffe A.B. Relationship of atypical antipsychotics with development of diabetes mellitus. Ann. Pharmacother. 37 (2003) 1849-1857
Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19 Suppl 1 (2005) 1-93
Bergman R.N., and Ader M. Atypical antipsychotics and glucose homeostasis. J. Clin. Psychiatry 66 (2005) 504-514
Holt A.I.G., and Peveler R.C. Association between antipsychotic drugs and diabetes. Diabetes Obes. Metab. 8 (2006) 125-135
Bottai T., and Quintin P. Perrin. Antipsychotics and the risk of diabetes: a general data review. Eur. Psychiatry 20 (2005) S349-S357
Ananth J., and Kolli S. Atypical antipsychotic agents and increased risk of diabetes: class action or differential action?. Expert Opin. Drug Saf. 4 (2005) 55-68
Jin H., Meyer J.M., and Jeste D.V. Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr. Res. 71 (2004) 195-212
De Hert M., Van Winkel R., Van Eyck D., Hanssens L., Wampers M., Scheen A., et al. Oral glucose tolerance tests in treated patients with schizophrenia. Data to support an adaptation of the proposed guidelines for monitoring of patients on second-generation antipsychotics?. Eur. Psychiatry 21 (2006) 224-226
Van Winkel R., De Hert M., Van Eyck D., Hanssens L., Wampers M., Scheen A., et al. Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methods. J. Clin. Psychiatry 67 (2006) 1493-1500
Ryan M.C., and Thakore J.H. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci. 71 (2002) 249-257
Holt R.I.G., Peveler R.C., and Byrne C.D. Schizophrenia, the metabolic syndrome and diabetes. Diabet. Med. 21 (2004) 515-523
McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 80 (2005) 19-32
De Hert M., Van Eyck D., Hanssens L., Peuskens H., Thys E., Wampers M., et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr. Res. 83 (2006) 87-93
Hennekens C.H., Hennekens A.R., Hollar D., and Casey D.E. Schizophrenia and increased risks of cardiovascular disease. Am. Heart J. 150 (2005) 1115-1121
Henderson D.C. Schizophrenia and comorbid metabolic disorders. J. Clin. Psychiatry 66 6, Suppl (2005) 11-20
Marder S.R., Essock S.M., Miller A.L., Buchanan R.W., Casey D.E., and Davis J.M. Physical health monitoring of patients with schizophrenia. Am. J. Psychiatry 161 (2004) 1334-1349
De Nayer A., De Hert M., Scheen A., Van Gaal L., Peuskens J., and On behalf of the Consensus Group. Belgian consensus on metabolic problems associated with atypical antipsychotics. Int. J. Psychiatry Clin. Pract. 9 (2005) 130-137
Poulin M.J., Cortese L., Williams R., Wine N., and McIntyre R.S. Atypical antipsychotics in psychiatry practice: practical implications for clinical monitoring. Can. J. Psychiatry 50 (2005) 555-562
Cohn T.A., and Sernyak M.J. Metabolic monitoring for patients treated with antipsychotic medications. Can. J. Psychiatry 51 (2006) 492-501
Lean M.E., and Pajonk F.G. Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes. Diabetes Care 26 (2003) 1597-1605
Scheen A.J., and De Hert M. Diabète sucré iatrogène : l'exemple des antipsychotiques atypiques. Rev. Med. Liege 60 (2005) 455-460
Kohen D. Diabetes mellitus and schizophrenia: historical perspective. Br. J. Psychiatry 184 Suppl 47 (2004) S64-S66
De Hert M., Van Winkel R., Van Eyck D., Hanssens L., Wampers M., Scheen A., et al. Prevalence of the diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemiol Mental Health 2 (2006) 14 (27 June 2006)
Regenold W.T., Thapar R.K., Marano C., Gavirnemi S., and Kondapavuluru P.V. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J. Affect. Disord. 70 (2002) 19-26
Van Winkel R., De Hert M., Van Eyck D., Hanssens L., Wampers M., Scheen A., et al. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disord. (2007) (in press)
Hedenmalm K., Hagg S., Stahl M., Mortimer O., and Spigset O. Glucose intolerance with atypical antipsychotics. Drug Saf. 25 (2002) 1107-1116
Melkersson K., and Dahl M.-L. Adverse metabolic effects associated with atypical antipsychotics. Literature review and clinical implications. Drugs 64 (2004) 701-723
Newcomer J.W., and Haupt D.W. The metabolic effects of antipsychotic medications. Can. J. Psychiatry 51 (2006) 480-491
Koller E.A., Cross J.T., Doraiswamy P.M., and Malozowski S.N. Pancreatitis associated with atypical antipsychotics: from the Food and Drug Administration's MedWatch surveillance system and published reports. Pharmacotherapy 23 (2003) 1123-1130
Koller E., Schneider B., Bennett K., and Dubitsky G. Clozapine-associated diabetes. Am. J. Med. 111 (2001) 716-723
Koller E.A., Cross J.T., Doraiswamy P.M., and Schneider B.S. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy 23 (2003) 735-744
Koller E.A., Weber J., Doraiswamy P.M., and Schneider B.S. A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J. Clin. Psychiatry 65 (2004) 857-863
Sernyak M.J., Leslie D.L., Alarcon R.D., Losonczy M.F., and Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am. J. Psychiatry 159 (2002) 561-566
Haddad P.M. Antipsychotics and diabetes: review of non-prospective data. Br. J. Psychiatry Suppl. 47 (2004) S80-S86
Koro C.E., Fedder D.O., L'Italien G.J., Weiss S., Magder L.S., Kreyenbuhl J., et al. An assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 325 (2002) 243-245
Kornegay C.J., Vasilakis-Scaramozza C., and Jick H. Incident diabetes associated with antipsychotic use in the United Kingdom general practice research database. J. Clin. Psychiatry 63 (2002) 758-762
Gianfrancesco F., White R., Wang R.H., and Nasrallah H.A. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J. Clin. Psychopharmacol. 23 (2003) 328-335
Buse J.B., Cavazzoni P., Hornbuckle K., Hutchins D., Breier A., and Jovanovic L. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J. Clin. Epidemiol. 56 (2003) 164-170
Lieberman J.A., Phillips M., Gu H., Stroup S., Zhang P., Kong L., et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs. chlorpromazine. Neuropsychopharmacol 28 (2003) 995-1003
Holt R.I.G., and Peveler R.C. Antipsychotic drugs and diabetes: an application of the Austin Bradford Hill criteria. Diabetologia 49 (2006) 1467-1473
Lieberman J.A., Stroup T.S., McEvoy J.P., et al., For the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353 (2006) 1209-1223
Scheen A.J., De Hert M.A., Hanssens L., Wampers M., van Winkel R., Van Eyck D., et al. (Abstract) Anomalies de la tolérance au glucose chez les patients schizophrènes traités par antipsychotiques de seconde génération : étude comparative prospective de trois mois. Diabetes Metab. 68 Suppl 1 (2007) 1S129
De Hert M., Hanssens L., Van Winkel R., Wampers M., Van Eyck D., Scheen A., et al. Reversibility of antipsychotic treatment-related diabetes in patients with schizophrenia. A case series of switching to aripiprazole. Diabetes Care 29 (2006) 2329-2330
Ader M., Kim S.P., Catalano K.J., Ionut V., Hucking K., Richey J.M., et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 54 (2005) 862-871
Johnson D.E., Yamazaki H., Ward K.M., Schmidt A.W., Lebel W.S., Treadway J.L., et al. Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets. Role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. Diabetes 54 (2005) 1552-1558
Gough S., and Pelever R. Diabetes and its prevention: pragmatic solutions for people with schizophrenia. Br. J. Psychiatr. 184 (2004) S106-S111
De Hert M., van Eyck D., and De Nayer A. Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring. Int. Clin. Psychopharmacol. 21 Suppl 2 (2006) S11-S15
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.